An interventional study of SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve ) and Placebo group in Sepsis and Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.
Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 8 with no phase, reaches primary completion later than 2 of the 15 other live ones, and was the 11th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 210 across the 17 interventional studies, 110 across the 13 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06851078Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial | 2027-06-15 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis is one of the leading causes of death in intensive care. About 50% of patients with septic shock die after 1 year; and 50% of survivors suffer from cognitive decline. The pathophysiological mechanisms of serious complications of sepsis are now well known. In fact, the systemic inflammation related to sepsis amplifies the release of pro-inflammatory cytokines and neurotoxic mediators, hence an increase in deleterious phenomena such as oxidative stress, mitochondrial dysfunction, endothelial activation, disruption of the blood-brain barrier, neuroinflammation (astrocytic and microglial activation) leading to multi-organ failure which compromises the patient's vital and functional prognosis. Although there has been progress in the understanding of its pathophysiology, the management of sepsis and septic shock in intensive care relies mainly on anti-infective treatments and the restoration of cardiovascular and respiratory functions. There is virtually no adjuvant therapy for the management of sepsis, apart from a few hormonal therapies such as insulin to maintain blood glucose levels below 180 mg / dL and low doses of corticosteroids and vasopressin. There is therefore a pressing need to develop innovative treatments targeting inflammatory and immunological processes in order to reduce the complications of sepsis and improve patient prognosis. Some recent work has shown that electrical vagus nerve stimulation (SNV), a technique used for the treatment of drug-resistant epilepsy, can modulate inflammatory and immune responses and control inflammation syndrome in animal models of sepsis, arthritis and rheumatism in humans. In this pilot study the investigators plan to evaluate the efficacy of transcutaneous (non-invasive) SNV as an adjuvant treatment in patients with sepsis in intensive care.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 30 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )
For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
Other: Placebo group
A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
Mortality
Overall death
Time frame: at day 90
Cumulative incidence of delirium and its duration
Time frame: up to day 90
Cumulative incidence of mechanical ventilation and its duration
Time frame: up to day 90
Proportion of patients having been the subject of a decision to limit or withdraw care
Time frame: at day 90
Duration of use of vasopressors
Time frame: at day 90
Number of days alive with a Sequential Organ Failure Assessment Score (SOFA) score <6
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function
Time frame: at day 90
Length of stay in intensive care and hospitalization in all patients and in survivors
Time frame: at day 90
Measurements of changes in C-reactive protein (CRP)
Time frame: at inclusion
Measurements of changes in C-reactive protein (CRP)
Time frame: at day 7
Measurements of changes in C-reactive protein (CRP)
Time frame: at day 14
Measurements of changes in C-reactive protein (CRP)
Time frame: at day 21
Measurements of changes in C-reactive protein (CRP)
Time frame: at day 28
Measurements of changes in C-reactive protein (CRP)
Time frame: at day 90
Measurements of changes in fibrinogen level
Time frame: at inclusion
Measurements of changes in fibrinogen level
Time frame: at day 7
Measurements of changes in fibrinogen level
Time frame: at day 14
Measurements of changes in fibrinogen level
Time frame: at day 21
Measurements of changes in fibrinogen level
Time frame: at day 28
Measurements of changes in fibrinogen level
Time frame: at day 90
Measurements of changes in interleukin-6 (IL-6)
Time frame: at inclusion
Measurements of changes in interleukin-6 (IL-6)
Time frame: at day 7
Measurements of changes in interleukin-6 (IL-6)
Time frame: at day 14
Measurements of changes in interleukin-6 (IL-6)
Time frame: at day 21
Measurements of changes in interleukin-6 (IL-6)
Time frame: at day 28
Measurements of changes in interleukin-6 (IL-6)
Time frame: at day 90
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at inclusion
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at day 7
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at day 14
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at day 21
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at day 28
Measurements of changes in interleukin-1β (IL-1β)
Time frame: at day 90
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at inclusion
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at day 7
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at day 14
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at day 21
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at day 28
Measurements of changes in tumor necrosis factor α (TNF-α)
Time frame: at day 90
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at inclusion
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at day 7
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at day 14
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at day 21
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at day 28
Measurements of changes in the calcium binding protein B S100B (S100B)
Time frame: at day 90
Measurements of changes in the arterial lactate level
Time frame: at inclusion
Measurements of changes in the arterial lactate level
Time frame: at day 7
Measurements of changes in the arterial lactate level
Time frame: at day 14
Measurements of changes in the arterial lactate level
Time frame: at day 21
Measurements of changes in the arterial lactate level
Time frame: at day 28
Measurements of changes in the arterial lactate level
Time frame: at day 90
Characteristics of the EEG
Time frame: at inclusion
Characteristics of the EEG
Time frame: at day 7
Mortality rate
Overall death
Time frame: at day 28
Neurological fate of patients
Neurological fate of patients will evaluated using Glasgow Outcome Scale (GOS)
Time frame: at day 90
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Mar 2025, 48 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 48 months is above that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →